Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 randomized, single-blind, single-dose, 3 arm, parallel group PK similarity, safety, tolerability, immunogenicity and bridging between HUMIRA® (US) and HUMIRA® (EU) in healthy subjects

Next Previous
Trial Profile

Phase 1 randomized, single-blind, single-dose, 3 arm, parallel group PK similarity, safety, tolerability, immunogenicity and bridging between HUMIRA® (US) and HUMIRA® (EU) in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Amgen

Most Recent Events

  • 02 Feb 2022 Results of retrospective analysis assessing PK equivalence between Adalimumab and ABP 501 in the presence of antidrug antibodies using population PK modeling, published in the Clinical Therapeutics
  • 04 May 2021 According to an Amgen media release, AMGEVITA was approved in Canada based on a robust data package supporting biosimilarity to the reference product, Humira, based on analytical, nonclinical, pharmacokinetic and clinical data, including results from two confirmatory clinical studies conducted in moderate-to-severe psoriasis (PsO) and moderate-to-severe rheumatoid arthritis (RA) patients.
  • 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top